Biomarkers For Metastatic Colon Cancer Treatment - Hallo friendsLET'S HEALTHY LIFE, In the article you read this time with the title Biomarkers For Metastatic Colon Cancer Treatment, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cough, Article diabetes, Article diseases, Article in general, Article Phytotherapy, Article skin diseases, We write this you can understand. Alright, good read.

Title : Biomarkers For Metastatic Colon Cancer Treatment
link : Biomarkers For Metastatic Colon Cancer Treatment

Biomarkers For Metastatic Colon Cancer Treatment

Metastatic colon cancer patients would benefit from having biomarkers analyzed, to judge potential response to certain therapeutic approaches.  This makes sense, as variation in signaling pathways can affect response to treatments, particularly those that target the altered pathways or other pathways that communicate with those altered.  Abstract:

BACKGROUND:

Metastatic colorectal cancer (mCRC) patients with mutant KRAS or NRAS are ineligible for anti-epidermal growth factor receptor (anti-EGFR) therapy, as RAS mutations activate downstream pathways independently of EGFR and induce primary resistance. However, even among RAS wild-type (WT) patients, only a fraction responds to anti-EGFR therapy, suggesting that other mechanisms of resistance exist. We hypothesise that different (epi)genetic alterations can lead to primary anti-EGFR resistance and that the crucial end point is the activation of protein signalling pathways.

METHODS:

We analysed the expression and activation of proteins involved in cell signalling, using reverse phase protein arrays, on a multicentre French cohort of RAS WT mCRC treated with anti-EGFR treatment.

RESULTS:

We identify activated EGFR and HER3 as protein biomarkers predictive for better overall survival. Active EGFR signalling and downstream PI3K, but not MAPK, pathway activation are associated with response to anti-EGFR treatment. Left-sided mCRC displays active ErbB2/3 and Wnt pathways and a better response to anti-EGFR therapy compared to right-sided mCRC.

CONCLUSIONS:

We identify active EGFR and PI3K signalling as a key factor for response to anti-EGFR treatment in mCRC and highlight the importance of developing these biomarkers in clinical practice for the selection of RAS WT mCRC patients that would benefit from anti-EGFR treatment. British Journal of Cancer advance online publication 12 October 2017; doi:10.1038/bjc.2017.353 www.bjcancer.com.

Thus Article Biomarkers For Metastatic Colon Cancer Treatment

That's an article Biomarkers For Metastatic Colon Cancer Treatment This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Biomarkers For Metastatic Colon Cancer Treatment with the link address https://letslifes.blogspot.com/2017/10/biomarkers-for-metastatic-colon-cancer.html

Tweet

Subscribe to receive free email updates: